All In Biotech

Drug Trial Radar · NCT05802329

Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)

A Phase 1 Study To Assess The Safety And Efficacy Of OCU200 For Center-Involved Diabetic Macular Edema

Last checked: Nov 20, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Jan 13, 2024

Primary completion

Jul 31, 2026

Study completion Jul 31, 2026

Sponsor

Lead sponsor
OcugenIndustry
Sponsor type
Industry
First posted
Apr 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Phase 1 study to assess the safety and efficacy of OCU200 for center-involved diabetic macular edema

Conditions

  • Center Involved Diabetic Macular Edema
  • Diabetic Macular Edema

Interventions

  • OCU200Drug

    Intravitreal Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Study Drug-related adverse events (SDAE)Time frame: 24 weeks
  2. Treatment-emergent adverse events (TEAEs)Time frame: 24 weeks
  3. Serious adverse events (SAEs)Time frame: 24 weeks

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Advanced Research LLC

    Deerfield Beach, Florida · Recruiting

  • Erie Retina Research, LLC

    Erie, Pennsylvania · Recruiting

  • Retina Consultants of Texas Research Centers

    Bellaire, Texas · Recruiting

  • Retina Consultants of America

    Southlake, Texas · Recruiting

  • Gundersen Health System

    La Crosse, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.